Fig. 6

In vivo study: injection of cryopreserved/thawed GMP day 21 Tregs from 1 KT and 1 LT patient in a xenogeneic GVHD murine model. a, c Show the percentage of body weight variation of mice receiving CD8−CD25− T cells only, GMP Tregs only or GMP Tregs plus CD8−CD25− T cells from KT and LT patients, respectively. Data are presented as means (KT/LT: CD8−CD25− T cells n = 7/8 mice; GMP Tregs n = 6/6 mice; GMP Tregs plus KT CD8−CD25− T cells n = 12/12 mice). b, d Show the survival rate of mice receiving CD8−CD25− T cells only, GMP Tregs only or GMP Tregs plus KT CD8−CD25− T cells from KT and LT patients, respectively. [Survival of mice receiving KT cells: statistically significant differences were observed only for Tregs versus CD8−CD25+ cells (p < 0.001) and Tregs versus CD8−CD25+cells+ Tregs (p < 0.01); survival of mice receiving LT cells: statistically significant differences were observed only for Tregs versus CD8−CD25+ cells (p < 0.05)]. Overall, mice receiving GMP Tregs plus CD8−CD25− T cells showed a trend toward a time delay in body weight loss and survival as compared with mice injected with CD8−CD25− T cells only